Improvement of European translational cancer research. Collaboration between comprehensive cancer centers

Even though the increasing incidence of cancer is mainly a consequence of a population with a longer life span, part of this augmentation is related to the increasing prevalence of patients living with a chronic cancer disease. To fight the problem, improved preventive strategies are mandatory in combination with an innovative health care provision that is driven by research. To overcome the weakness of translational research the OECI is proposing a practical approach as part of a strategy foreseen by the EUROCAN+PLUS feasibility study, which was launched by the EC in order to identify mechanisms for the coordination of cancer research in Europe

Standardized postnatal management of infants with congenital diaphragmatic hernia in Europe: The CDH EURO Consortium Consensus - 2015 Update

In 2010, the congenital diaphragmatic hernia (CDH) EURO Consortium published a standardized neonatal treatment protocol. Five years later, the number of participating centers has been raised from 13 to 22. In this article the relevant literature is updated, and consensus has been reached between the members of the CDH EURO Consortium. Key updated recommendations are: (1) planned delivery after a gestational age of 39 weeks in a high-volume tertiary center; (2) neuromuscular blocking agents to be avoided during initial treatment in the delivery room; (3) adapt treatment to reach a preductal saturation of between 80 and 95% and postductal saturation >70%; (4) target PaCO2 to be between 50 and 70 mm Hg; (5) conventional mechanical ventilation to be the optimal initial ventilation strategy, and (6) intravenous sildenafil to be considered in CDH patients with severe pulmonary hypertension. This article represents the current opinion of all consortium members in Europe for the optimal neonatal treatment of CDH

Conception, synthèse et évaluations d'analogues de l'ifosfamide à moindres neurotoxicité et néphrotoxicité induites

L ifosfamide, (IFO) est un agent bisalkylant cytotoxique. L IFO est largement utilisé, tant en onco-pédiatrie que chez l adulte, dans le traitement des tumeurs des tissus mous mais aussi en seconde ligne en hématologie. L IFO possède comme d autres agents alkylants un effet-dose . A fortes doses, des effets secondaires néphrologique et neurologique placent les cliniciens dans une impasse thérapeutique. La voie catabolique de l IFO conduisant au chloroacétaldéhyde (CAA) est fortement corrélée à ces toxicités. Objectif : Diminuer ces toxicités tout en maintenant une activité cytotoxique. Moyens : 1/ Synthèse chimique et caractérisation d analogues de l IFO 2/ Evaluation de l activité alkylante des analogues (Suivi cinétique par RMN 31P, anabolisme biomimétique par électrochimie, cytotoxicité en présence de CYP450) 3/ Evaluation de la diminution des toxicités (métabolisation microsomale, études in vitro). D autres part, la préactivation électrochimique en position 4 de l IFO a été étudiée.Ifosfamide is a useful prodrug with CYP450 metabolisation associated to both antitumor activity and toxicities. Current evidence suggests that chloroacetaldehyde, a side-chain oxidation metabolite is responsible for neurotoxicity and nephrotoxicity. The aim of our research is to prevent chloroacetaldehyde formation. First, we designed and synthesized new enantioselective synthesized ifosfamide analogues i.e. C7,C9-dimethyl-ifosfamide. Two topics were investigated. First, metabolites determination of the IFO analogues was performed using HPLC-MS after in vitro biotransformation by drug-induced rat liver microsomes. Secondly, the cytotoxicity of these prodrugs was evaluated. Finally, a mechanistic study using 31P-NMR kinetics allowed to estimate the alkylating activity of the modified mustards. Secondly, electrochemical biomimetic oxidation and preactivation of IFO were studied. This is a first step toward vectorisation of IFO.PARIS-BIUP (751062107) / SudocPARIS-Académie Médecine (751065201) / SudocSudocFranceF

La supplémentation en calcium chez les adolescents atteints de MICI [Maladies inflammatoires chroniques de l'intestin]

PARIS-BIUP (751062107) / SudocSudocFranceF

The Experience of Childhood and the Learning Society: Allowing the Child to be Philosophical and Philosophy to be Childish

Both 'philosophy' and 'the child' are notions that seem to have an everlasting presence in our daily vocabulary. What is less common and perhaps lacking is any reflection on the relation between them, which is rarely a focus of the researcher's attention. We believe that it is precisely this relation that is at stake in increasingly popular notions such as 'philosophy for/with children', or even in philosophy of education as such. In this article we will expand upon this claim by exploring the meeting place(s) of both notions. An extensive elaboration of this relation would need not only more space than the average journal article offers, but also much more extensive research. Both 'philosophy' and 'the child'-if we were to do justice to the wealth these terms offer-should each form separately the object of further research, in order to be able to pick the fruits of their shared household. We will bypass a labyrinthine study of this sort, however, and instead offer some thoughts on the cross-section of both these terms, seeking as it were what could be philosophical about the child, and where philosophy becomes childish. We hope that the reader would be so kind as to step into this brief, and somewhat associative, reasoning and find something of value in this wordplay, knowing that the more extensive treatise that the interconnection of these two realities demands is to be found elsewhere. The authors, for their part, are writing in the conviction that less can sometimes be more. © 2011 The Author. Journal compilation © 2011 Journal of the Philosophy of Education Society of Great Britain.status: publishe

Prise en charge de la douleur lors de la vaccination chez le nouveau-né prématuré

PARIS-BIUP (751062107) / SudocSudocFranceF

Dosage par spectroscopie proche infrarouge du chlorhydrate de pioglitazone dans des gélules destinées au traitement de l'ataxie de Friedreich

PARIS-BIUP (751062107) / SudocSudocFranceF